

REMARKS

Claims 1-3 are pending. Amendments have been made in response to the last office action mailed November 3, 2008. No new matter has been added thereby.

Objection to the Specification

The specification has been objected to for not containing an abstract on a separate sheet, and has been amended to include an abstract on a separate sheet.

Claim Objections

Claim 1 has been objected to for containing particular "errors," and has been amended to change the spelling of "sulphur" to "sulfur."

Rejection Under 35 U.S.C. §112, First Paragraph


Claims 1 and 3 have been rejected as not enabled for solvates, esters, polymorphs or metabolites of the compounds of Formula I. The claims have been amended to delete these phrases. Reconsideration and withdrawal of the rejection on these grounds is requested.

CONCLUSION

Applicants submit that all pending claims are now allowable, and request a Notice of Allowance at the next opportunity from the Office. Authorization is hereby given to charge any fees deemed to be due in connection with this Response to Deposit Account No. 50-0912.

Respectfully submitted,

MEHTA et al.

By: 
George E. Heibel, Ph.D.
Reg. No. 42,648

Date: January 29, 2009

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel: (609) 720-5334
Fax: (609) 514-9779